Cardax to Lead Aging Discussion at Chaminade University

Download as PDF

HONOLULU-- Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that it will be leading a discussion on aging at Chaminade University’s Public Policy Forum series on October 28, 2015.

Cardax CEO David G. Watumull and Cardax Scientific Advisory Board member Bradley J. Willcox, MD will discuss the therapeutic and commercial potential of recent scientific discoveries that connect inflammation and aging with an emphasis on the role Hawaii can play as a global center for longevity.

The Chaminade Public Policy Forums bring together 30-50 “opinion leaders” on an “invitation only” basis to interact around a chosen topic of importance to the community and is hosted by Chaminade University President Bernard Ploeger.

About Cardax

Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing consumer health and pharmaceutical products that it believes will provide many of the anti-inflammatory benefits of steroids or NSAIDS by targeting many of the same inflammatory pathways and mediators, but with exceptional safety profiles. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding. The safety and efficacy of Cardax's product candidates have not been directly evaluated in clinical trials or confirmed by the FDA.

About Bradley J. Willcox, MD

Dr. Willcox is Principal Investigator of the National Institute on Aging-funded Kuakini Hawaii Lifespan Study and Kuakini Healthspan Study, which are ancillary studies on aging from the Kuakini Honolulu Heart Program. He is also Professor and Director of Research at the Department of Geriatric Medicine, John A. Burns School of Medicine, University of Hawaii. Dr. Willcox is the Co-Principal Investigator of the Okinawa Centenarian Study and has been investigating mechanisms of aging for over two decades with this study.

Dr. Willcox’s research teams have identified several genetic and environmental risk factors for aging and aging-related chronic diseases, especially cardiovascular diseases. His research team in Okinawa identified the first longevity-associated gene (Takata et al., Lancet, 1987) that was replicated in an independent population. His research team in Hawaii was the first to identify the association (widely replicated since) of the FOXO3 gene on human longevity (Willcox et al., PNAS, 2008), and the first to replicate the protective effect on longevity of the CETP gene, and the first to extend the CETP gene’s role to include human healthspan (Koropatnick et al., J Gerontol A Biol Sci Med Sci, 2008). These genes appear to act, at least in part, through cardiovascular pathways to influence healthy aging and mortality.

Dr. Willcox has published widely in the genetic, environmental, and clinical aspects of healthy aging. He is on the Editorial Board of several leading gerontological journals, including the Journals of Gerontology (Biological and Medical Sciences). He is a frequent reviewer for major medical journals and is on the Board of Scientific Counselors (BSC) for the National Institute on Aging (NIA), which reviews all intramural NIA research programs, among other honors. Dr. Willcox is also the author of a New York Times best-selling book on healthy aging. His work has appeared in cover articles of Time Magazine, National Geographic, and on Oprah, Good Morning America, NOVA Science, BBC, and other media.

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

Cardax, Inc.
Janice Kam, 1-808-457-1400
press@cardaxpharma.com

Source: Cardax, Inc.

Released October 6, 2015